With EU Notified Body Numbers Tumbling, How Do Manufacturers Ensure Seamless Transition To MDR?
Executive Summary
Device manufacturers in the EU are beginning to realize the extra volume of MDR/IVDR-related work that their pivotal market access partners, the notified bodies, will have to take on. With the regulations' three- and five-year transition period clocks ticking down already, manufacturers must make sure that business continuity is guaranteed – but it won't be easy.
You may also be interested in...
EU Medtech Ecosystem Will Suffer Unless Notified Body Workload Concerns Are Addressed – The German View
An EU notified body redesignation rate of 10 per year is too slow. It won't help small companies using the new Medical Device and IVD Regulation systems, and is leaving NBs feeling let down and with a mountain to climb. A German industry group weighs in on the need to speed up redesignations.
EU MDR Set To Rack Up Costs For Industry, German Medtechs Say
Prepare for notified body bottlenecks and skyrocketing clinical evaluation costs for medical devices as you comply with the EU Medical Device Regulation (MDR): that's what German medtech industry delegates were told at a legal and regulatory symposium last week.
UK Medtech One Year Post-Brexit Vote: Still In The Land of Uncertainty
The UK's Brexit and a failed Conservative Party election strategy last month weigh heavily on the minds of local medtech businesses, looking ahead nervously at the type of trade deal the UK might finally strike with the EU. They could be waiting a while, because the When and What are still not yet apparent – never mind that the Why still rankles with many UK medtechs. That much is clear from a brand new survey of companies, which also reveals the primacy of NHS access.